Biostem has developed a hair restoration process known as The Biostem Method^TM. This process offered through Biostem affiliates and licensees, involves the use of platelet rich plasma injections, low level laser therapy, nutraceutical supplements to stimulate stem cell growth, and private labeled hair products. This combination has proven highly effective in restoring hair growth in men and women. In mid 2012, the company will begin offering it’s licensing and affiliate programs worldwide. The first operational affiliate is located in Ohio.

Harness the Power of your own body’s stem cells
Stem Cell Therapy with platelet rich plasma (PRP) uses the body’s own cells to target your hair restoration needs. The equipment used for soft tissue injection is cleared by the FDA and Biostem’s affiliates/licensees are actively involved in applying PRP technology to hair restoration.

STEP 1: About five days prior to your procedure, you begin taking Biostem Support, a Biostem supplement formulated in association with leading researchers from a major southern Florida university. This completely natural nutraceutical enhances your body’s ability to produce and release adult stem cells which results in the presence of more cells in your blood on the day of your procedure.

STEP 2: : In-office procedure, where your own blood is drawn and your stem cells are harvested in our on-site, state-of-the-art, laboratory facility. Special laboratory technology is used to separate the platelet rich plasma containing your stem cells and growth factors from your blood, then is injected back into your scalp targeting the areas where your current hair growth is diminishing.

STEP 3: You leave the Biostem affiliate’s clinic looking no different in appearance than when you came in. The entire procedure takes about an hour and is virtually painless. You can resume normal daily activity immediately upon leaving the clinic.

Key Benefits:

• Virtually painless procedure.

• Non-obvious to others; no embarrassing dressings or bandages.

• Takes approximately an hour to complete initial treatment.

• Non-invasive.

• Safe, with no side effects.

Investor Highlights

• HAIR announced that Dr. Prendergast is appointed Chief of Cardiothoracic Surgery at St. Francis Hospital. Dr. Prendergast is a clinical cardiothoracic surgeon, who performs 200-250 open-heart operations and 5 to 15 heart transplants each year. He is deeply involved in numerous clinical and research activities associated with stem cells and heart repair. He is presently Director of Cardiac Transplantation at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, where he holds an Associate Professorship of Surgery at the University of Medicine and Dentistry of New Jersey. In addition to being an active participant in stem cell research program development and teaching medical students and residents, his other interests include medical research funding and humanitarian development of programs for Disabled American Veterans.

• HAIR has entered into a contractual affiliate agreement with Dr. Marina Pizarro and her multi-location practice, Pizarro Hair Restoration Clinics www.DrPizarro.com. Additionally, Dr. Pizarro will serve as the Medical Director for the company. Dr. Marina Pizarro holds the distinction of being the first female hair transplant physician in the industry and belongs to the elite group of surgeons who have performed over 30,000 hair transplant procedures in their careers. She received her Medical Degree from Ponce School of Medicine in Puerto Rico in 1985.

• HAIR has engaged Acropolis Inc. www.acropolisinc.com, a full-service advertising agency located in Orlando, Florida, to lend their expertise in brand building, marketing, and advertising development and placement.

• Philip A. Lowry, MD, has been appointed as the Chairman of its Scientific and Medical Board of Advisors . Dr. Philip A. Lowry received his undergraduate degree from Harvard College before going on to the Yale University School of Medicine. His completed his internal medicine residency at the University of Virginia then pursued fellowship training in hematology and oncology there as well. During fellowship training and subsequently at the University of Massachusetts, he worked in the laboratory of Dr. Peter Quesenberry working on in vitro and in vivo studies of mouse and human stem cell biology.

• In May HAIR announced a $5,000,000 financing agreement through private placement of stock. CEO, Dwight Brunoehler, The company issued issue 20,000,000 shares of the company’s common stock in exchange for $5,000,000 in cash or 25 cents ($.25) per share.

• Jeanne Ann Lumadue, MD, PhD, MBA, has been appointed to its Scientific and Medical Board of Advisors . Dr. Lumadue currently is Medical Director at the Mount Nittany Physician Group Laboratory in State College, PA. She also serves as Medical Director of the Central Pennsylvania Blood Bank and is a member of the medical staff of the Mount Nittany Medical Center, all in State College.

• Late last year, John Satino, President of Biostem, announced results of a two year consumer study, on treating Alopecia Areata, conducted at a Biostem affiliate clinic in Florida at The international Stem Cell & Cicatrical Alopecia Symposium. The Symposium was held in Bethesda, Maryland and sponsored by Case Western Reserve School of Medicine and The National Institutes of Health Rare Disease Research Office. The study involved 700 patients, with results showing renewed hair growth in 80% of the participants. The treatment, developed by Biostem, includes a combination of the patients own blood, utilization of growth factors, laser treatments for bio-photo stimulation, and a nutraceutical designed to stimulate hair follicle growth. This unique combination of treatments is known as “The Biostem Method™.”